Moleculin Biotech (MBRX) Reports Q1 Result

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. BA
6. SPY
7. META
8. HOOD
9. INTC
10. JBLU

Go back to Moleculin Biotech (MBRX) Reports Q1 Result

Moleculin Reports First Quarter 2022 Financial Results and Provides Programs Update

May 12, 2022 8:35 AM EDT

Positive advancements, encouraging preclinical and clinical data, and development activity in all three core technologies

Multiple key clinical and regulatory milestones expected throughout 2022  

Company has sufficient capital to fund operations into 2024  

HOUSTON, May 12, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today reported its financial results for the quarter ended March 31, 2022. The Company also provided an update on its portfolio of oncology drug... More